Biogen has given investors a pleasant surprise with better-than-expected profits in Q3, but has puzzled analysts with a rapid slowdown for its new rare disease drug Spinraza.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
